We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · July 29, 2021

Onasemnogene Abeparvovec in Spinal Muscular Atrophy

JAMA Neurology


Additional Info

JAMA Neurology
Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy
JAMA Neurol 2021 Jul 01;78(7)834-841, JR Mendell, SA Al-Zaidy, KJ Lehman, M McColly, LP Lowes, LN Alfano, NF Reash, MA Iammarino, KR Church, A Kleyn, MN Meriggioli, R Shell

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading